Thyrocare Technologies Limited
THYROCARE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹235.61.
Piotroski F-score 8/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%28.7%
- ✓Low debt (D/E < 0.5)0.09x
- ✓Positive free cash flow
- ✓Revenue growth > 10%20%
- ✓Earnings growing116%
- ✓Net margin ≥ 10%19.7%
- ✓Current ratio > 1.53.39
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 33.39
- ✓Piotroski ≥ 78/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Analyst views
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (28.7%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (19.7%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 33.39.
- •High Piotroski quality score (8/9).
Opportunities
- •Earnings growing (116% YoY).
- •Revenue growing (20% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~45% above our estimated fair value.
About Thyrocare Technologies Limited
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.